Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Documentation on the Use of Apremilast in Patients With Psoriatic Arthritis in Practice Conditions

Next Previous
Trial Profile

Long-term Documentation on the Use of Apremilast in Patients With Psoriatic Arthritis in Practice Conditions

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms LAPIS-PsA
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 04 Sep 2019 Planned End Date changed from 30 Jun 2019 to 31 Jul 2020.
    • 15 Jun 2019 Results of interim analysis (n=394) assessing the clinical effectiveness of Apremilast as measured with the Clinical Disease activity index for PsA (cDAPSA) presented at the 20th Annual Congress of the European League Against Rheumatism
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top